{"dataset":"assessments","methodology_version":"ev-1","license":{"id":"CC-BY-4.0","name":"Creative Commons Attribution 4.0 International","url":"https://creativecommons.org/licenses/by/4.0/","note":"Peptide Library's classifications, counts and statistics are licensed under CC BY 4.0: reuse them with attribution to Peptide Library. Bibliographic identifiers, titles and dates are facts from PubMed (courtesy of the U.S. National Library of Medicine), Europe PMC, ClinicalTrials.gov, OpenAlex (CC0) and Crossref, used under their terms. No abstracts or full texts are included."},"rows":[{"kind":"claim","tool":null,"title":"Improves function in Barth syndrome","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"barth-syndrome","peptide_id":"elamipretide","review_mode":"automated","subject_key":"barth-syndrome","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Improves dry eye signs and symptoms","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"dry-eye","peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"dry-eye","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Improves gastrointestinal conditions","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"gastrointestinal-outcomes","peptide_id":"bpc-157","review_mode":"automated","subject_key":"gastrointestinal-outcomes","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Is safe for human administration","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"human-safety","peptide_id":"bpc-157","review_mode":"automated","subject_key":"human-safety","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Is safe for human administration","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"human-safety","peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"human-safety","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Is safe for human administration","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"human-safety","peptide_id":"mots-c","review_mode":"automated","subject_key":"human-safety","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Is safe for human administration","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"human-safety","peptide_id":"elamipretide","review_mode":"automated","subject_key":"human-safety","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Is safe for human administration","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"human-safety","peptide_id":"tb-500","review_mode":"automated","subject_key":"human-safety","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Is safe for human use","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"human-safety","peptide_id":"ghk-cu","review_mode":"automated","subject_key":"human-safety","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Supports soft-tissue injury recovery","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"injury-recovery","peptide_id":"tb-500","review_mode":"automated","subject_key":"injury-recovery","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Reduces knee pain","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"knee-pain","peptide_id":"bpc-157","review_mode":"automated","subject_key":"knee-pain","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Improves metabolic health","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"metabolic-health","peptide_id":"mots-c","review_mode":"automated","subject_key":"metabolic-health","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Improves exercise capacity in primary mitochondrial myopathy","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"mitochondrial-myopathy","peptide_id":"elamipretide","review_mode":"automated","subject_key":"mitochondrial-myopathy","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Improves muscle injury recovery","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"muscle-injury-recovery","peptide_id":"bpc-157","review_mode":"automated","subject_key":"muscle-injury-recovery","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Improves signs of skin aging","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"skin-aging","peptide_id":"ghk-cu","review_mode":"automated","subject_key":"skin-aging","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"claim","tool":null,"title":"Supports tendon injury recovery","status":"published","outcome":null,"version":1,"judgment":null,"study_key":null,"claim_slug":"tendon-recovery","peptide_id":"bpc-157","review_mode":"automated","subject_key":"tendon-recovery","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Is safe for human administration","status":"published","outcome":"Adverse events, serious adverse events and discontinuations","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"human-safety","peptide_id":"tb-500","review_mode":"automated","subject_key":"grade-1","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Improves metabolic health","status":"published","outcome":"Insulin sensitivity, glucose control or body weight","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"metabolic-health","peptide_id":"mots-c","review_mode":"automated","subject_key":"grade-10","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":0,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Improves function in Barth syndrome","status":"published","outcome":"Muscle strength, exercise capacity and fatigue","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"barth-syndrome","peptide_id":"elamipretide","review_mode":"automated","subject_key":"grade-11","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":31,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Improves exercise capacity in primary mitochondrial myopathy","status":"published","outcome":"Six-minute walk distance and fatigue","version":1,"judgment":"low","study_key":null,"claim_slug":"mitochondrial-myopathy","peptide_id":"elamipretide","review_mode":"automated","subject_key":"grade-12","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":284,"conclusion_type":"conflicting","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Is safe for human administration","status":"published","outcome":"Adverse events, including injection-site reactions, and discontinuations","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"human-safety","peptide_id":"elamipretide","review_mode":"automated","subject_key":"grade-13","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":655,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Is safe for human administration","status":"published","outcome":"Adverse events, serious adverse events and discontinuations","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"human-safety","peptide_id":"bpc-157","review_mode":"automated","subject_key":"grade-14","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":14,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Improves dry eye signs and symptoms","status":"published","outcome":"Ocular discomfort and corneal staining","version":1,"judgment":"very_low","study_key":null,"claim_slug":"dry-eye","peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"grade-15","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":81,"conclusion_type":"conflicting","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Is safe for human administration","status":"published","outcome":"Adverse events, serious adverse events and discontinuations","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"human-safety","peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"grade-16","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":318,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Supports soft-tissue injury recovery","status":"published","outcome":"Function and return to activity","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"injury-recovery","peptide_id":"tb-500","review_mode":"automated","subject_key":"grade-2","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Improves gastrointestinal conditions","status":"published","outcome":"Clinical response or remission","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"gastrointestinal-outcomes","peptide_id":"bpc-157","review_mode":"automated","subject_key":"grade-3","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Improves muscle injury recovery","status":"published","outcome":"Time to return to activity","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"muscle-injury-recovery","peptide_id":"bpc-157","review_mode":"automated","subject_key":"grade-4","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Supports tendon injury recovery","status":"published","outcome":"Function and return to activity","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"tendon-recovery","peptide_id":"bpc-157","review_mode":"automated","subject_key":"grade-5","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Is safe for human administration","status":"published","outcome":"Adverse events, serious adverse events and discontinuations","version":1,"judgment":"insufficient_information","study_key":null,"claim_slug":"human-safety","peptide_id":"mots-c","review_mode":"automated","subject_key":"grade-6","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Reduces knee pain","status":"published","outcome":"Knee pain intensity","version":1,"judgment":"very_low","study_key":null,"claim_slug":"knee-pain","peptide_id":"bpc-157","review_mode":"automated","subject_key":"grade-7","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":17,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Improves signs of skin aging","status":"published","outcome":"Wrinkles and skin quality, measured or rated","version":1,"judgment":"very_low","study_key":null,"claim_slug":"skin-aging","peptide_id":"ghk-cu","review_mode":"automated","subject_key":"grade-8","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":14,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"grade","tool":"grade","title":"Is safe for human use","status":"published","outcome":"Adverse events, including skin reactions","version":1,"judgment":"very_low","study_key":null,"claim_slug":"human-safety","peptide_id":"ghk-cu","review_mode":"automated","subject_key":"grade-9","needs_update":false,"published_at":"2026-11-08T08:05:02.790507+00:00","tool_version":"GRADE (handbook, 2013)","search_cutoff":"2026-11-08","n_participants":1001,"conclusion_type":"insufficient","source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu.","status":"published","outcome":"Wrinkles","version":1,"judgment":"serious_concern","study_key":"PLS-00025","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-1","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).","status":"published","outcome":"Pain during treatment","version":1,"judgment":"serious_concern","study_key":"PLS-00027","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-10","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":"Geographic atrophy area","version":1,"judgment":"serious_concern","study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-100","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":"Low-luminance questionnaire (LLQ) self-reported function","version":1,"judgment":"serious_concern","study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-101","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.","status":"published","outcome":"Change in left ventricular end systolic volume (LVESV)","version":1,"judgment":"some_concerns","study_key":"PLS-00115","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-102","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.","status":"published","outcome":"Change in left ventricular ejection fraction (LVEF)","version":1,"judgment":"some_concerns","study_key":"PLS-00115","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-103","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.","status":"published","outcome":"Study drug-related adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00115","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-104","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"6-minute walk test distance","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-105","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"PMMSA Total Fatigue score","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-106","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"PMMSA Total Fatigue During Activities score","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-107","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Neuro-QoL Fatigue Short Form","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-108","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Patient Global Assessment","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-109","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).","status":"published","outcome":"Adverse effects","version":1,"judgment":"serious_concern","study_key":"PLS-00027","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-11","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Physician Global Assessment","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-110","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Triple Timed Up and Go test","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-111","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Wrist and hip accelerometry","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-112","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-113","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.","status":"published","outcome":"Infarct size by CK-MB area under the curve over 72 h","version":1,"judgment":"some_concerns","study_key":"PLS-00117","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-114","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.","status":"published","outcome":"Pre-specified MRI, angiographic and electrocardiographic outcomes","version":1,"judgment":"high","study_key":"PLS-00117","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-115","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.","status":"published","outcome":"Clinical outcomes","version":1,"judgment":"high","study_key":"PLS-00117","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-116","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.","status":"published","outcome":"Safety and tolerability","version":1,"judgment":"high","study_key":"PLS-00117","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-117","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.","status":"published","outcome":"Left ventricular end-diastolic volume","version":1,"judgment":"high","study_key":"PLS-00120","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-118","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.","status":"published","outcome":"Left ventricular end-systolic volume","version":1,"judgment":"high","study_key":"PLS-00120","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-119","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.","status":"published","outcome":"Scar appearance (Manchester Scoring Scale)","version":1,"judgment":"serious_concern","study_key":"PLS-00028","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-12","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.","status":"published","outcome":"Serious adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00120","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-120","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.","status":"published","outcome":"6-minute walk test distance","version":1,"judgment":"serious_concern","study_key":"PLS-00106","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-121","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.","status":"published","outcome":"BTHS-SA Total Fatigue score","version":1,"judgment":"serious_concern","study_key":"PLS-00106","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-122","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.","status":"published","outcome":"Safety and tolerability","version":1,"judgment":"serious_concern","study_key":"PLS-00106","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-123","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.","status":"published","outcome":"3D echocardiographic left ventricular volumes","version":1,"judgment":"serious_concern","study_key":"PLS-00106","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-124","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.","status":"published","outcome":"MLCL/CL ratio","version":1,"judgment":"serious_concern","study_key":"PLS-00106","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-125","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","status":"published","outcome":"Mitochondrial energetic capacity (ATPmax) during exercise","version":1,"judgment":"some_concerns","study_key":"PLS-00121","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-126","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","status":"published","outcome":"Resting mitochondrial coupling (P/O, ATP supply per O2 uptake)","version":1,"judgment":"some_concerns","study_key":"PLS-00121","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-127","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","status":"published","outcome":"Volitional fatigue resistance","version":1,"judgment":"some_concerns","study_key":"PLS-00121","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-128","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.","status":"published","outcome":"Stenotic kidney fractional hypoxia","version":1,"judgment":"high","study_key":"PLS-00122","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-129","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.","status":"published","outcome":"Skin texture (smoothness, roughness, scaliness; Visioscan)","version":1,"judgment":"serious_concern","study_key":"PLS-00028","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-13","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.","status":"published","outcome":"Stenotic kidney renal blood flow","version":1,"judgment":"high","study_key":"PLS-00122","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-130","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.","status":"published","outcome":"Estimated glomerular filtration rate","version":1,"judgment":"high","study_key":"PLS-00122","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-131","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.","status":"published","outcome":"Systolic blood pressure","version":1,"judgment":"high","study_key":"PLS-00122","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-132","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.","status":"published","outcome":"Serum HtrA2 level","version":1,"judgment":"high","study_key":"PLS-00123","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-133","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).","status":"published","outcome":"CK-MB area under the curve (biomarker infarct size)","version":1,"judgment":"high","study_key":"PLS-00125","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-134","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).","status":"published","outcome":"Troponin I area under the curve (biomarker infarct size)","version":1,"judgment":"high","study_key":"PLS-00125","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-135","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).","status":"published","outcome":"Myocardial salvage index","version":1,"judgment":"high","study_key":"PLS-00125","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-136","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.","status":"published","outcome":"Infarcted area","version":1,"judgment":"high","study_key":"PLS-00134","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-137","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.","status":"published","outcome":"Adherent Scalp Flaking Score","version":1,"judgment":"no_information","study_key":"PLS-00143","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-138","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.","status":"published","outcome":"Maximum Erythema Area","version":1,"judgment":"no_information","study_key":"PLS-00143","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-139","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.","status":"published","outcome":"Adverse effects and in-use tolerability","version":1,"judgment":"serious_concern","study_key":"PLS-00028","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-14","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.","status":"published","outcome":"Scalp physiological conditions (transepidermal water loss, hydration, sebum secretion)","version":1,"judgment":"no_information","study_key":"PLS-00143","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-140","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.","status":"published","outcome":"Scalp microbiome composition and diversity","version":1,"judgment":"no_information","study_key":"PLS-00143","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-141","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.","status":"published","outcome":"Treatment-emergent adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00149","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-142","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.","status":"published","outcome":"Dose-limiting toxicities and serious adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00149","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-143","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.","status":"published","outcome":"Pharmacokinetic parameters","version":1,"judgment":"some_concerns","study_key":"PLS-00149","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-144","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"The effect of thymosin treatment of venous ulcers.","status":"published","outcome":"Safety and tolerability","version":1,"judgment":"high","study_key":"PLS-00156","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-145","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"The effect of thymosin treatment of venous ulcers.","status":"published","outcome":"Complete wound healing","version":1,"judgment":"high","study_key":"PLS-00156","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-146","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"The effect of thymosin treatment of venous ulcers.","status":"published","outcome":"Rate of wound healing","version":1,"judgment":"high","study_key":"PLS-00156","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-147","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study.","status":"published","outcome":"6-minute walking distance","version":1,"judgment":"high","study_key":"PLS-00167","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-148","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study.","status":"published","outcome":"Left ventricular function","version":1,"judgment":"high","study_key":"PLS-00167","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-149","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults.","status":"published","outcome":"Adherent Scalp Flaking Score (ASFS)","version":1,"judgment":"serious_concern","study_key":"PLS-00029","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-15","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study.","status":"published","outcome":"Feasibility and safety","version":1,"judgment":"high","study_key":"PLS-00167","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-150","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.","status":"published","outcome":"Adverse events / tolerability","version":1,"judgment":"some_concerns","study_key":"PLS-00173","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-151","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.","status":"published","outcome":"Pharmacokinetics (plasma concentration, Cmax, AUC, terminal clearance, accumulation)","version":1,"judgment":"some_concerns","study_key":"PLS-00173","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-152","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.","status":"published","outcome":"Ocular discomfort score","version":1,"judgment":"some_concerns","study_key":"PLS-00174","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-153","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.","status":"published","outcome":"Inferior corneal staining","version":1,"judgment":"some_concerns","study_key":"PLS-00174","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-154","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.","status":"published","outcome":"Ocular discomfort during CAE challenge","version":1,"judgment":"high","study_key":"PLS-00174","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-155","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.","status":"published","outcome":"Central corneal staining","version":1,"judgment":"high","study_key":"PLS-00174","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-156","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.","status":"published","outcome":"Superior corneal staining","version":1,"judgment":"high","study_key":"PLS-00174","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-157","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.","status":"published","outcome":"Adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00174","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-158","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.","status":"published","outcome":"Ocular discomfort (OSDI questionnaire)","version":1,"judgment":"high","study_key":"PLS-00201","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-159","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"The effects of hydroporation on melasma with anti-aging cocktail.","status":"published","outcome":"Clinical pigmentation and erythema","version":1,"judgment":"serious_concern","study_key":"PLS-00030","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-16","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.","status":"published","outcome":"Total corneal fluorescein staining","version":1,"judgment":"high","study_key":"PLS-00201","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-160","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.","status":"published","outcome":"Tear film breakup time","version":1,"judgment":"high","study_key":"PLS-00201","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-161","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.","status":"published","outcome":"Tear volume production","version":1,"judgment":"high","study_key":"PLS-00201","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-162","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.","status":"published","outcome":"Safety and tolerability","version":1,"judgment":"high","study_key":"PLS-00201","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"rob-163","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"The effects of hydroporation on melasma with anti-aging cocktail.","status":"published","outcome":"Melanin index","version":1,"judgment":"serious_concern","study_key":"PLS-00030","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-17","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"The effects of hydroporation on melasma with anti-aging cocktail.","status":"published","outcome":"Erythema index","version":1,"judgment":"serious_concern","study_key":"PLS-00030","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-18","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"The effects of hydroporation on melasma with anti-aging cocktail.","status":"published","outcome":"Dermal type IV collagen and procollagen","version":1,"judgment":"serious_concern","study_key":"PLS-00030","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-19","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu.","status":"published","outcome":"Skin barrier condition","version":1,"judgment":"serious_concern","study_key":"PLS-00025","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-2","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"The effects of hydroporation on melasma with anti-aging cocktail.","status":"published","outcome":"p63-positive cells along basement membrane","version":1,"judgment":"serious_concern","study_key":"PLS-00030","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-20","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.","status":"published","outcome":"Percentage area closure of plantar ulcers","version":1,"judgment":"some_concerns","study_key":"PLS-00031","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-21","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.","status":"published","outcome":"Proportion of patients healing 98% or better","version":1,"judgment":"some_concerns","study_key":"PLS-00031","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-22","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.","status":"published","outcome":"Rate of ulcer closure","version":1,"judgment":"some_concerns","study_key":"PLS-00031","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-23","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.","status":"published","outcome":"Percentage area closure in larger plantar ulcers (>100 mm2 at entry)","version":1,"judgment":"high","study_key":"PLS-00031","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-24","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.","status":"published","outcome":"Incidence of ulcer infection","version":1,"judgment":"high","study_key":"PLS-00031","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-25","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.","status":"published","outcome":"Blood biomarkers of heart, liver, kidney, thyroid function and blood glucose","version":1,"judgment":"serious_concern","study_key":"PLS-00033","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"rob-26","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.","status":"published","outcome":"Side effects / tolerability","version":1,"judgment":"serious_concern","study_key":"PLS-00033","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"rob-27","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.","status":"published","outcome":"Improvement in knee pain (patient-reported)","version":1,"judgment":"serious_concern","study_key":"PLS-00034","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"rob-28","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.","status":"published","outcome":"Global Response Assessment","version":1,"judgment":"serious_concern","study_key":"PLS-00035","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"rob-29","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.","status":"published","outcome":"Resolution of post-treatment erythema","version":1,"judgment":"high","study_key":"PLS-00026","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-3","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.","status":"published","outcome":"Patient-rated symptom resolution","version":1,"judgment":"serious_concern","study_key":"PLS-00035","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"rob-30","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.","status":"published","outcome":"Adverse events and dropouts","version":1,"judgment":"serious_concern","study_key":"PLS-00035","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"rob-31","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.","status":"published","outcome":"Hair fall on hair pull test","version":1,"judgment":"serious_concern","study_key":"PLS-00032","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-32","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.","status":"published","outcome":"Vellus hairs, terminal hairs and shaft diameter","version":1,"judgment":"serious_concern","study_key":"PLS-00032","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-33","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.","status":"published","outcome":"Patient-perceived benefit","version":1,"judgment":"serious_concern","study_key":"PLS-00032","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-34","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.","status":"published","outcome":"Total hair count","version":1,"judgment":"serious_concern","study_key":"PLS-00032","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-35","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.","status":"published","outcome":"Tolerability","version":1,"judgment":"serious_concern","study_key":"PLS-00032","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-36","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Left ventricular ejection fraction (LVEF)","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-37","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Mitral regurgitation severity","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-38","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Ross heart failure class","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-39","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.","status":"published","outcome":"Overall improvement in wrinkles","version":1,"judgment":"high","study_key":"PLS-00026","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-4","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Functional capacity / exercise tolerance","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-40","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Nutritional status","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-41","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Health-related quality of life","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-42","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Return to school","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-43","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Heart transplant listing status","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-44","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":"Adverse events / tolerability","version":1,"judgment":"serious_concern","study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-45","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.","status":"published","outcome":"Symptoms and quality of life","version":1,"judgment":"serious_concern","study_key":"PLS-00098","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-46","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.","status":"published","outcome":"Tolerability","version":1,"judgment":"serious_concern","study_key":"PLS-00098","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-47","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.","status":"published","outcome":"Left ventricular ejection fraction","version":1,"judgment":"serious_concern","study_key":"PLS-00099","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-48","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.","status":"published","outcome":"Oxygen weaning and hospital discharge","version":1,"judgment":"serious_concern","study_key":"PLS-00099","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-49","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.","status":"published","outcome":"Overall improvement in skin appearance","version":1,"judgment":"high","study_key":"PLS-00026","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-5","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.","status":"published","outcome":"Six-minute walk test distance, overall trial population","version":1,"judgment":"some_concerns","study_key":"PLS-00100","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-50","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.","status":"published","outcome":"Six-minute walk test distance, prespecified nDNA and mtDNA subgroups","version":1,"judgment":"some_concerns","study_key":"PLS-00100","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-51","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.","status":"published","outcome":"Six-minute walk test change, mtDNA replisome post hoc cohort","version":1,"judgment":"high","study_key":"PLS-00100","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-52","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.","status":"published","outcome":"Six-minute walk test change, replisome subjects with CPEO","version":1,"judgment":"high","study_key":"PLS-00100","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-53","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.","status":"published","outcome":"Exposure-response: plasma elamipretide concentration vs 6MWT improvement, nDNA cohort","version":1,"judgment":"high","study_key":"PLS-00100","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-54","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.","status":"published","outcome":"Tolerability of elamipretide","version":1,"judgment":"serious_concern","study_key":"PLS-00101","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-55","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.","status":"published","outcome":"Cardiac transplantation and clinical course","version":1,"judgment":"serious_concern","study_key":"PLS-00101","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-56","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.","status":"published","outcome":"Explanted heart pathology","version":1,"judgment":"serious_concern","study_key":"PLS-00101","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-57","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.","status":"published","outcome":"Clinical heart failure status and heart transplant listing status","version":1,"judgment":"serious_concern","study_key":"PLS-00102","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-58","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.","status":"published","outcome":"Symptoms (dysarthria, dysphagia, gait)","version":1,"judgment":"serious_concern","study_key":"PLS-00103","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-59","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.","status":"published","outcome":"Patient-reported improvement in overall skin quality (questionnaire)","version":1,"judgment":"high","study_key":"PLS-00026","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-6","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.","status":"published","outcome":"6-minute walk test","version":1,"judgment":"serious_concern","study_key":"PLS-00103","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-60","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.","status":"published","outcome":"5 times sit-to-stand test","version":1,"judgment":"serious_concern","study_key":"PLS-00103","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-61","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.","status":"published","outcome":"Mean change from baseline in low-luminance best-corrected visual acuity (LL BCVA)","version":1,"judgment":"some_concerns","study_key":"PLS-00104","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-62","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.","status":"published","outcome":"Change from baseline in square-root converted geographic atrophy area","version":1,"judgment":"some_concerns","study_key":"PLS-00104","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-63","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.","status":"published","outcome":"Progression of macular percentage of total ellipsoid zone attenuation/loss","version":1,"judgment":"some_concerns","study_key":"PLS-00104","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-64","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.","status":"published","outcome":"Progression of macular percentage of partial ellipsoid zone attenuation/degradation","version":1,"judgment":"some_concerns","study_key":"PLS-00104","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-65","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.","status":"published","outcome":"Proportion of patients with a gain of 10 or more letters in LL BCVA","version":1,"judgment":"some_concerns","study_key":"PLS-00104","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-66","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.","status":"published","outcome":"Incidence and severity of adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00104","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-67","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.","status":"published","outcome":"Adverse events","version":1,"judgment":"some_concerns","study_key":"PLS-00105","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-68","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.","status":"published","outcome":"Change from baseline in best-corrected visual acuity (BCVA)","version":1,"judgment":"some_concerns","study_key":"PLS-00105","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-69","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).","status":"published","outcome":"Periorbital wrinkles (crow's feet)","version":1,"judgment":"serious_concern","study_key":"PLS-00027","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-7","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.","status":"published","outcome":"Central visual field mean deviation (Humphrey automated visual field central region)","version":1,"judgment":"high","study_key":"PLS-00105","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-70","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.","status":"published","outcome":"6-minute walk test distance","version":1,"judgment":"some_concerns","study_key":"PLS-00107","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-71","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.","status":"published","outcome":"PMMSA total fatigue score","version":1,"judgment":"some_concerns","study_key":"PLS-00107","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-72","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.","status":"published","outcome":"Adverse events","version":1,"judgment":"high","study_key":"PLS-00107","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-73","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.","status":"published","outcome":"Accuracy of clustering patients by functional status from wearable physiological data","version":1,"judgment":"high","study_key":"PLS-00109","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-74","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.","status":"published","outcome":"Accuracy of clustering responders vs non-responders to elamipretide","version":1,"judgment":"high","study_key":"PLS-00109","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-75","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.","status":"published","outcome":"6-minute walk test distance","version":1,"judgment":"no_information","study_key":"PLS-00110","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-76","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.","status":"published","outcome":"Muscle strength by handheld dynamometry","version":1,"judgment":"no_information","study_key":"PLS-00110","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-77","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.","status":"published","outcome":"5 times sit-to-stand","version":1,"judgment":"no_information","study_key":"PLS-00110","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-78","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.","status":"published","outcome":"Multi-domain responder index","version":1,"judgment":"no_information","study_key":"PLS-00110","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-79","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).","status":"published","outcome":"Dermal collagen on histology","version":1,"judgment":"serious_concern","study_key":"PLS-00027","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-8","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"robins-i","title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.","status":"published","outcome":"Left ventricular stroke volume","version":1,"judgment":"no_information","study_key":"PLS-00110","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-80","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"ROBINS-I (2016)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Change in 6-minute walk test distance","version":1,"judgment":"high","study_key":"PLS-00111","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-81","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Cardiopulmonary exercise testing parameters","version":1,"judgment":"some_concerns","study_key":"PLS-00111","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-82","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Participant-reported symptoms","version":1,"judgment":"some_concerns","study_key":"PLS-00111","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-83","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Serum and urinary biomarkers","version":1,"judgment":"some_concerns","study_key":"PLS-00111","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-84","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"rob2","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":"Safety and tolerability","version":1,"judgment":"some_concerns","study_key":"PLS-00111","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-85","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"RoB 2 (2019-08-22)","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Adverse events and tolerability","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-86","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Normal-luminance best-corrected visual acuity (BCVA)","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-87","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Low-luminance best-corrected visual acuity (LLVA)","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-88","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Normal-luminance binocular reading acuity (NLRA)","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-89","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).","status":"published","outcome":"Dermal matrix proteins (collagen IV, fibrillin-1, procollagen type 1, tropoelastin)","version":1,"judgment":"serious_concern","study_key":"PLS-00027","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"rob-9","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Low-luminance binocular reading acuity (LLRA)","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-90","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"RPE-drusen complex volume by OCT","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-91","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Fundus autofluorescence","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-92","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Mesopic microperimetry","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-93","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":"Dark adaptation","version":1,"judgment":"serious_concern","study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-94","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":"Safety and tolerability (adverse events)","version":1,"judgment":"serious_concern","study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-95","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":"Normal-luminance best-corrected visual acuity (BCVA)","version":1,"judgment":"serious_concern","study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-96","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":"Low-luminance best-corrected visual acuity (LLBCVA)","version":1,"judgment":"serious_concern","study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-97","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":"Low-luminance binocular reading acuity (LLBRA)","version":1,"judgment":"serious_concern","study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-98","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"rob","tool":"structured_appraisal","title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":"Normal-luminance binocular reading acuity (NLBRA)","version":1,"judgment":"serious_concern","study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"rob-99","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":"Peptide Library structured appraisal pl-1","search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Phase II trial of PL 14736 (BPC-157) enema in mild-to-moderate ulcerative colitis","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00001","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00001","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Phase 1 safety, tolerability and pharmacokinetics of PL 14736 (BPC-157) in healthy male volunteers","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00002","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00002","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00025","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00025","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00026","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00026","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00027","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00027","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00028","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00028","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00029","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00029","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The effects of hydroporation on melasma with anti-aging cocktail.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00030","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00030","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00031","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00031","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00032","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00032","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00033","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00033","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00034","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00034","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00035","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00035","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00036","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00036","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00037","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00037","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00038","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00038","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00039","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00039","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00040","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00040","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MOTS-c is associated with oxidative stress and arterial stiffness in peritoneal dialysis patients: a pilot study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00041","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00041","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The Association Between Serum MOTS-c Levels and Myocardial Ischemia-Reperfusion Injury in Patients with Acute Myocardial Infarction: A Cross-Sectional Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00042","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00042","needs_update":false,"published_at":"2026-11-07T19:30:07.193509+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00043","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00043","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00044","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00044","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00045","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00045","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00046","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00046","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00047","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00047","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00048","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00048","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"AGEs-RAGE Axis and Mitochondrial-Derived Peptides in Advanced Chronic Kidney Disease: Interconnected Pathways Beyond Inflammation and Nutrition.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00049","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00049","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer's Disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00050","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00050","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Reduced serum levels of mitochondria-derived peptide MOTS-c in patients with obstructive sleep apnea.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00051","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00051","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Circulating levels of MOTS-c in patients with breast cancer treated with metformin.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00052","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00052","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00053","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00053","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Circulating mitochondrial biomarkers in acute coronary syndrome.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00054","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00054","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00055","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00055","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Could MOTS-c Levels in Children with Type 1 Diabetes Mellitus Be an Indicator for Early Diabetic Kidney Disease?","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00056","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00056","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MOTS-c as a Potential Diagnostic-prognostic Biomarker for Myocardial Infarction.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00057","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00057","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00058","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00058","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Evaluation of vascular peroxidase 1, humanin, MOTS-c and miR-200c expression levels in untreated preeclampsia patients.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00059","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00059","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00060","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00060","needs_update":false,"published_at":"2026-11-07T20:35:03.614508+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Relationship between the mitochondria-derived peptide MOTS-c and insulin resistance in obstructive sleep apnea.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00061","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00061","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00062","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00062","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00063","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00063","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00064","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00064","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00065","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00065","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00066","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00066","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Mitochondrial dysfunction is associated with cognitive impairment in adults with OSA without dementia.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00067","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00067","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00068","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00068","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MOTS-c Serum Concentration Positively Correlates with Lower-Body Muscle Strength and Is Not Related to Maximal Oxygen Uptake-A Preliminary Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00069","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00069","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00070","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00070","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00071","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00071","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Evaluation of Coronary Flow Level with Mots-C in Patients with STEMI Undergoing Primary PCI.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00072","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00072","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Serum MOTS-C Levels are Decreased in Obese Children and Associated with Vascular Endothelial Function.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00073","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00073","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00074","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00074","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00075","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00075","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00076","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00076","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Evaluation of Serum Humanin and MOTS-c Peptide Levels in Patients with COVID-19 and Healthy Subjects.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00077","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00077","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00078","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00078","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Serum MOTS-c levels remain unchanged in patients with preeclampsia.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00079","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00079","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00080","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00080","needs_update":false,"published_at":"2026-11-07T21:40:03.474518+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00081","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00081","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00082","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00082","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Adropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke?","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00083","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00083","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00084","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00084","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The Effect of Chronic Endurance Exercise on Serum Levels of MOTS-c and Humanin in Professional Athletes.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00085","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00085","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Alterations in circulating mitochondrial signals at hospital admission for COPD exacerbation.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00086","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00086","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00087","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00087","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Changes in MOTS-c Level in the Blood of Pregnant Women with Metabolic Disorders.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00088","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00088","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00089","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00089","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00090","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00090","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00091","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00091","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00092","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00092","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00093","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00093","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The Relationship Between MOTS-c K14Q Polymorphism and Sarcopenia, Blood Lipids, and Mental Health in Older Korean Adults.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00094","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00094","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00095","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00095","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00096","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00096","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Elamipretide in pediatric Barth syndrome: from heart failure to school return.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00097","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00097","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00098","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00098","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00099","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00099","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00100","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00100","needs_update":false,"published_at":"2026-11-07T22:45:04.509122+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00101","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00101","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00102","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00102","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00103","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00103","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00104","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00104","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00105","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00105","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00106","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00106","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00107","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00107","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00108","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00108","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00109","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00109","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00110","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00110","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00111","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00111","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00112","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00112","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00113","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00113","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00114","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00114","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00115","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00115","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00116","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00116","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00117","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00117","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00118","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00118","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00119","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00119","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00120","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00120","needs_update":false,"published_at":"2026-11-07T23:50:03.506977+00:00","tool_version":null,"search_cutoff":"2026-11-07","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00121","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00121","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00122","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00122","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00123","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00123","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00124","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00124","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00125","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00125","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Low periconceptional maternal serum thymosin alpha 1 levels are associated with blighted pregnancies.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00126","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00126","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00127","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00127","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin alpha 1 and thymosin beta 4 in serum: comparison of normal, cord, homosexual and AIDS serum.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00128","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00128","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00129","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00129","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00130","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00130","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Modulation of thymosin beta 4 by estrogen.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00131","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00131","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosins: structure, function and therapeutic applications.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00132","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00132","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00133","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00133","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00134","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00134","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Association between Thymosin beta-4, acute kidney injury, and mortality in patients with sepsis: An observational cohort study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00135","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00135","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Longitudinal Trends of Salivary Oxidized Thymosin β4 and β10 in Preterm Infants with Bronchopulmonary Dysplasia.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00136","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00136","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Hypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00137","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00137","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Association Between Thymosin β4 and Coronary Arterial Lesions in Children with Kawasaki Disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00138","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00138","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00139","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00139","needs_update":false,"published_at":"2026-11-08T01:00:08.076392+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin β4, a potential marker of malignancy and prognosis in hepatocellular carcinoma.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00140","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00140","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00141","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00141","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00142","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00142","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00143","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00143","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Association between thymosin beta4 and non-alcoholic fatty liver disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00144","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00144","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin beta-4 overexpression correlates with high-risk groups in gastric gastrointestinal stromal tumors: A retrospective analysis by immunohistochemistry.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00145","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00145","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Exploring the Relationship Between Thymosin β4 Protein and First Myocardial Infarction on the Basis of Proteomics.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00146","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00146","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00147","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00147","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin β4 and β10 are highly expressed at the deep infiltrative margins of colorectal cancer - A mass spectrometry analysis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00148","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00148","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00149","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00149","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Comparative proteomic analysis of plasma of children with congenital heart disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00150","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00150","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Identification and quantification of thymosin beta4 in human saliva and tears.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00151","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00151","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"F-Actin is associated with a worsening qSOFA score and intensive care unit admission in emergency department patients at risk for sepsis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00152","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00152","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Endogenous Thymosin β4 Expression in Sacrococcygeal Pilonidal Sinus Disease: A Retrospective, Immunohistochemical Analysis of Excisional Skin Biopsy Samples.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00153","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00153","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Conjunctival expression of thymosin-beta4 in vernal keratoconjunctivitis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00154","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00154","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00155","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00155","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The effect of thymosin treatment of venous ulcers.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00156","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00156","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00157","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00157","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin ß4 expression in colorectal polyps and adenomas.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00158","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00158","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin beta4 levels after successful primary percutaneous coronary intervention for acute myocardial infarction.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00159","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00159","needs_update":false,"published_at":"2026-11-08T01:36:01.568212+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin beta 4 is associated with collateral development in coronary artery disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00160","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00160","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00161","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00161","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00162","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00162","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00163","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00163","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Association of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00164","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00164","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Determination of thymosin beta4 and protein in human wound fluid after abdominal surgery.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00165","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00165","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00166","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00166","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00167","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00167","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00168","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00168","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MALDI imaging mass spectrometry analysis-A new approach for protein mapping in multiple sclerosis brain lesions.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00169","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00169","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Association of thymosin β4 expression with clinicopathological parameters and clinical outcomes of bladder cancer patients.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00170","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00170","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Discovery of thymosin β4 as a human exerkine and growth factor.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00171","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00171","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosinβ4: a novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient?","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00172","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00172","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00173","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00173","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00174","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00174","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Plasma levels of F-actin and F:G-actin ratio as potential new biomarkers in patients with septic shock.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00175","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00175","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00176","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00176","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00177","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00177","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00178","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00178","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Over-expression of thymosin β4 in granulomatous lung tissue with active pulmonary tuberculosis.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00179","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00179","needs_update":false,"published_at":"2026-11-08T02:45:04.105978+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Increased levels of thymosin β4 in synovial fluid of patients with rheumatoid arthritis: association of thymosin β4 with other factors that are involved in inflammation and bone erosion in joints.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00180","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00180","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00181","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00181","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c₁ complex subunit 1 as serological diagnostic biomarkers of gastric cancer.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00182","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00182","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Quantification of thymosin beta(4) in human cerebrospinal fluid using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00183","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00183","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00184","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00184","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin beta(4) and beta(10) levels in pre-term newborn oral cavity and foetal salivary glands evidence a switch of secretion during foetal development.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00185","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00185","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00186","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00186","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00187","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00187","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effect of vitamin A deficiency on thymosin-β4 and CD4 concentrations.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00188","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00188","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Serum Thymosin β4 Concentrations in Obstructive Sleep Apnea Syndrome Patients.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00189","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00189","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin β4 is a novel potential prognostic marker in gastrointestinal stromal tumors.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00190","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00190","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin β4 and β10 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00191","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00191","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00192","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00192","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Contribution of cerebrospinal fluid thymosin β4 levels to the clinical differentiation of Creutzfeldt-Jakob disease.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00193","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00193","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Increased thymosin β4 levels in the serum and SF of knee osteoarthritis patients correlate with disease severity.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00194","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00194","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin β 4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00195","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00195","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Distribution of thymic hormones in thymic tumors and myasthenic thymus.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00196","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00196","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"β-Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00197","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00197","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00198","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00198","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Relationship between serum thymosin β4 levels and coronary collateral development.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00199","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00199","needs_update":false,"published_at":"2026-11-08T03:50:04.125403+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"From proteomic multimarker profiling to interesting proteins: thymosin-β(4) and kininogen-1 as new potential biomarkers for inflammatory hepatic lesions.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00200","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00200","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00201","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00201","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"[The clinical significance of thymosin β4 expression in human non-small cell lung cancer].","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00202","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00202","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Biochemical characterization of thymic hormones in thymoma tissues.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00203","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00203","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Multiplexed molecular descriptors of pressure ulcers defined by imaging mass spectrometry.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00204","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00204","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Intraocular expression of thymosin β4 in proliferative diabetic retinopathy.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00205","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00205","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Elevated expression of thymosin β4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in early-stage cervical cancers.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00206","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00206","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Associations of Serum MOTS-c with Exercise Capacity and Antioxidant Markers in Young Males: A Cross-Sectional Study.","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00207","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00207","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00208","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00208","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Study of Thymosin Beta 4 in Patients With Pressure Ulcers","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00209","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00209","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00210","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00210","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00211","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00211","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00212","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00212","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00213","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00213","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00214","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00214","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00215","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00215","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00216","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00216","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00217","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00217","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00218","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00218","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00219","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00219","needs_update":false,"published_at":"2026-11-08T04:55:01.881083+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00220","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00220","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00221","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00221","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00222","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00222","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00223","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00223","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00224","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00224","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00225","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00225","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00226","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00226","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"PCO-02 - Safety and Pharmacokinetics Trial","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00227","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00227","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00228","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00228","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00229","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00229","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00230","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00230","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00231","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00231","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00232","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00232","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00233","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00233","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00234","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00234","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00235","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00235","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00236","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00236","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00237","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00237","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00238","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00238","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00239","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00239","needs_update":false,"published_at":"2026-11-08T05:55:03.280194+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"An Intermediate Size Expanded Access Protocol of Elamipretide","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00240","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00240","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00241","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00241","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"FRDA Investigator Initiated Study (IIS) With Elamipretide","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00242","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00242","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00243","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00243","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00244","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00244","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Study of Healthy Aging and Physical Function With Elamipretide","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00245","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00245","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"BPC 157 for Acute Hamstring Muscle Strain Repair","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00246","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00246","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Topical GHK-Cu Gel for Acute Skin Wound Healing","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00247","claim_slug":null,"peptide_id":"ghk-cu","review_mode":"automated","subject_key":"PLS-00247","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00248","claim_slug":null,"peptide_id":"tb-500","review_mode":"automated","subject_key":"PLS-00248","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00249","claim_slug":null,"peptide_id":"mots-c","review_mode":"automated","subject_key":"PLS-00249","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Clinical Trial in Patients With Barth Syndrome- 4TAZPower","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00250","claim_slug":null,"peptide_id":"elamipretide","review_mode":"automated","subject_key":"PLS-00250","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00251","claim_slug":null,"peptide_id":"thymosin-beta-4","review_mode":"automated","subject_key":"PLS-00251","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"},{"kind":"study","tool":null,"title":"Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery","status":"published","outcome":null,"version":1,"judgment":null,"study_key":"PLS-00252","claim_slug":null,"peptide_id":"bpc-157","review_mode":"automated","subject_key":"PLS-00252","needs_update":false,"published_at":"2026-11-08T07:05:02.178479+00:00","tool_version":null,"search_cutoff":"2026-11-08","n_participants":null,"conclusion_type":null,"source_snapshot":"2026.1.1","methodology_version":"ev-1"}]}